- Report
- April 2025
- 50 Pages
Global
From €2412EUR$2,650USD£2,068GBP
- Report
- May 2024
- 128 Pages
Global
From €5915EUR$6,499USD£5,071GBP
- Drug Pipelines
- April 2024
- 40 Pages
Global
From €1138EUR$1,250USD£975GBP
Mosapride is a gastroprokinetic drug used to treat gastrointestinal disorders such as gastroesophageal reflux disease (GERD), functional dyspepsia, and irritable bowel syndrome (IBS). It is a selective serotonin 5-HT4 receptor agonist that increases gastrointestinal motility and reduces gastric acid secretion. Mosapride is available in both oral and intravenous formulations and is used in combination with other drugs to treat gastrointestinal disorders.
Mosapride is a relatively new drug in the gastrointestinal market and is gaining popularity due to its efficacy and safety profile. It is generally well tolerated and has few side effects. Mosapride is also cost-effective compared to other drugs used to treat gastrointestinal disorders.
Some companies in the Mosapride market include Astellas Pharma, Daiichi Sankyo, Takeda Pharmaceuticals, and Shionogi & Co. Ltd. Show Less Read more